News >

Hall Addresses Selection for Chemoimmunotherapy in NSCLC

Angelica Welch
Published: Monday, Sep 10, 2018

Richard D. Hall, MD

Richard D. Hall, MD

Immunotherapy has continued to expand its role in the non–small cell lung cancer (NSCLC) treatment landscape over the last few years. Now, recent data with combinations and a growing understanding of molecular abnormalities have raised questions over who is best eligible for immunotherapy and where it will optimally work, said Richard D. Hall, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication